Newsroom
Newsroom
Newsroom
Latest Learnings
Get the latest insights, news, and expert articles from Model Medicines.
LAtest News
Jan 28, 2025
Announcement
Model Medicines Unveils Generative AI, Multi-Modal Therapeutic Pipeline Breakthrough, Demonstrating End-To-End Drug Discovery Capabilities
Jan 28, 2025
Announcement
Model Medicines Unveils Generative AI, Multi-Modal Therapeutic Pipeline Breakthrough, Demonstrating End-To-End Drug Discovery Capabilities
Jan 28, 2025
Announcement
Model Medicines Unveils Generative AI, Multi-Modal Therapeutic Pipeline Breakthrough, Demonstrating End-To-End Drug Discovery Capabilities
Jan 26, 2025
Pre-Print
Demonstrating End-to-End Drug Discovery: GALILEO™ Unlocks Generative AI for Chemistry
Jan 26, 2025
Pre-Print
Demonstrating End-to-End Drug Discovery: GALILEO™ Unlocks Generative AI for Chemistry
Jan 26, 2025
Pre-Print
Demonstrating End-to-End Drug Discovery: GALILEO™ Unlocks Generative AI for Chemistry
Jan 21, 2025
Announcement
Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral
Jan 21, 2025
Announcement
Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral
Jan 21, 2025
Announcement
Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral
Jan 14, 2025
Pre-Print
MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases
Jan 14, 2025
Pre-Print
MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases
Jan 14, 2025
Pre-Print
MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases
Jun 5, 2024
Announcement
Model Medicines Announces Nomination of Preclinical Candidate, MDL-4101, Targeting BRD4 for the Treatment of Thyroid Cancer
Jun 5, 2024
Announcement
Model Medicines Announces Nomination of Preclinical Candidate, MDL-4101, Targeting BRD4 for the Treatment of Thyroid Cancer
Jun 5, 2024
Announcement
Model Medicines Announces Nomination of Preclinical Candidate, MDL-4101, Targeting BRD4 for the Treatment of Thyroid Cancer
Apr 24, 2024
Announcement
Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor
Apr 24, 2024
Announcement
Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor
Apr 24, 2024
Announcement
Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor
Apr 9, 2024
Announcement
Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers
Apr 9, 2024
Announcement
Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers
Apr 9, 2024
Announcement
Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers
Apr 8, 2024
Pre-Print
Model Medicines Reveals Breakthrough AI Discovery: RdRp Thumb-1, A Universal RNA Antiviral Target, and MDL-001, a Potent Inhibitor
Apr 8, 2024
Pre-Print
Model Medicines Reveals Breakthrough AI Discovery: RdRp Thumb-1, A Universal RNA Antiviral Target, and MDL-001, a Potent Inhibitor
Apr 8, 2024
Pre-Print
Model Medicines Reveals Breakthrough AI Discovery: RdRp Thumb-1, A Universal RNA Antiviral Target, and MDL-001, a Potent Inhibitor
Mar 20, 2024
Announcement
Model Medicines Discovers New Pan-Antiviral Chemical Entity (NCE) Library, Achieving Unprecedented 66.7% Hit Rate Using Proprietary AI Platform
Mar 20, 2024
Announcement
Model Medicines Discovers New Pan-Antiviral Chemical Entity (NCE) Library, Achieving Unprecedented 66.7% Hit Rate Using Proprietary AI Platform
Mar 20, 2024
Announcement
Model Medicines Discovers New Pan-Antiviral Chemical Entity (NCE) Library, Achieving Unprecedented 66.7% Hit Rate Using Proprietary AI Platform
Mar 11, 2024
Paper
Dissimilar, Drug-Like, Novel Chemical Entities (DDL-NCEs); Using Multimodal Generative AI
Mar 11, 2024
Paper
Dissimilar, Drug-Like, Novel Chemical Entities (DDL-NCEs); Using Multimodal Generative AI
Mar 11, 2024
Paper
Dissimilar, Drug-Like, Novel Chemical Entities (DDL-NCEs); Using Multimodal Generative AI
Nov 15, 2022
Events
Model Medicines Selected to Participate at the 5th Annual Evercore ISI HealthCONx Conference
Nov 15, 2022
Events
Model Medicines Selected to Participate at the 5th Annual Evercore ISI HealthCONx Conference
Nov 15, 2022
Events
Model Medicines Selected to Participate at the 5th Annual Evercore ISI HealthCONx Conference
Oct 4, 2022
Announcement
Model Medicines Announces Launch of Oncology Programs with Multiple AI-Discovered Compounds Demonstrating Drug-Like Activity for Two High Value, Difficult to Drug, Oncogenic and Epigenetic Targets
Oct 4, 2022
Announcement
Model Medicines Announces Launch of Oncology Programs with Multiple AI-Discovered Compounds Demonstrating Drug-Like Activity for Two High Value, Difficult to Drug, Oncogenic and Epigenetic Targets
Oct 4, 2022
Announcement
Model Medicines Announces Launch of Oncology Programs with Multiple AI-Discovered Compounds Demonstrating Drug-Like Activity for Two High Value, Difficult to Drug, Oncogenic and Epigenetic Targets
Apr 6, 2020
Press
Model Medicines Accepted To Join The Alliance for Artificial Intelligence in Healthcare (AAIH)
Apr 6, 2020
Press
Model Medicines Accepted To Join The Alliance for Artificial Intelligence in Healthcare (AAIH)
Apr 6, 2020
Press
Model Medicines Accepted To Join The Alliance for Artificial Intelligence in Healthcare (AAIH)
Mar 30, 2020
Press
Model Medicines COVID-19 Drug Development Program Highlighted by Catalyst Health 2.0
Mar 30, 2020
Press
Model Medicines COVID-19 Drug Development Program Highlighted by Catalyst Health 2.0
Mar 30, 2020
Press
